Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2015 1
2016 1
2017 1
2018 2
2019 5
2020 5
2021 4
2022 7
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology.
Macaluso FS, Papi C, Orlando A, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD); Working panel; Review panel. Macaluso FS, et al. Dig Liver Dis. 2023 Apr;55(4):442-453. doi: 10.1016/j.dld.2023.01.155. Epub 2023 Feb 13. Dig Liver Dis. 2023. PMID: 36792429 Free article.
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology.
Macaluso FS, Orlando A, Papi C, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD); Working panel; Review panel. Macaluso FS, et al. Dig Liver Dis. 2022 Apr;54(4):440-451. doi: 10.1016/j.dld.2022.01.127. Epub 2022 Feb 17. Dig Liver Dis. 2022. PMID: 35184989 Free article.
Nutritional Keys for Intestinal Barrier Modulation.
De Santis S, Cavalcanti E, Mastronardi M, Jirillo E, Chieppa M. De Santis S, et al. Among authors: mastronardi m. Front Immunol. 2015 Dec 7;6:612. doi: 10.3389/fimmu.2015.00612. eCollection 2015. Front Immunol. 2015. PMID: 26697008 Free PMC article. Review.
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study.
Ribaldone DG, Parisio L, Variola A, Bossa F, Castiglione F, Marzo M, Piazza N, Aratari A, Savarino EV, Bodini G, Mastronardi M, Micheli F, Mazzuoli S, Ascolani M, Viganò C, Cappello M, Bezzio C, Ciccocioppo R, Scardino G, Sarli E, Pugliese D, Scaldaferri F, Napolitano D, Todeschini A, Geccherle A, Colaci N, Guerra M, Annese M, Testa A, Caiazzo A, Conforti FS, Festa S, Lorenzon G, Marra A, Magiotta A, Baccini F, Amato A, Poshnjari A, Vernero M, Caprioli F, Caviglia GP; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Ribaldone DG, et al. Among authors: mastronardi m. Dig Liver Dis. 2024 Jan;56(1):77-82. doi: 10.1016/j.dld.2023.07.011. Epub 2023 Jul 19. Dig Liver Dis. 2024. PMID: 37474412
Dysbiosis Triggers ACF Development in Genetically Predisposed Subjects.
De Santis S, Liso M, Vacca M, Verna G, Cavalcanti E, Coletta S, Calabrese FM, Eri R, Lippolis A, Armentano R, Mastronardi M, De Angelis M, Chieppa M. De Santis S, et al. Among authors: mastronardi m. Cancers (Basel). 2021 Jan 14;13(2):283. doi: 10.3390/cancers13020283. Cancers (Basel). 2021. PMID: 33466665 Free PMC article.
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F, Armuzzi A; National patients’ association representatives. Fiorino G, et al. Dig Liver Dis. 2019 May;51(5):632-639. doi: 10.1016/j.dld.2019.02.004. Epub 2019 Feb 19. Dig Liver Dis. 2019. PMID: 30872085 Review.
31 results